Navigation Links
Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
Date:3/5/2013

Geneva, Switzerland (PRWEB) March 05, 2013

Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that the results from Company’s internal drug discovery platform R&D program have been published in Metabolic Engineering(1).

Publication Abstract
“CHO cell engineering to prevent polypeptide aggregation and improve therapeutic protein secretion”
The ability to efficiently produce recombinant proteins in a secreted form is highly desirable and cultured mammalian cells such as CHO cells have become the preferred host as they secrete proteins with human-like post-translational modifications. However, attempts to express high levels of particular proteins in CHO cells may consistently result in low yields, even for non-engineered proteins such as immunoglobulins. In this study, we identified the responsible faulty step at the stage of translational arrest, translocation and early processing for such a ‘‘difficult-to-express’’ immunoglobulin, resulting in improper cleavage of the light chain and its precipitation in an insoluble cellular fraction unable to contribute to immunoglobulin assembly. We further show that proper processing and secretion were restored by over-expressing human signal receptor protein SRP14 and other components of the secretion pathway. This allowed the expression of the difficult-to-express protein to high yields, and it also increased the production of an easy-to-express protein. Our results demonstrate that components of the secretory and processing pathways can be limiting, and that engineering of the secretory pathway may be used to improve the secretion efficiency of therapeutic proteins from CHO cells.

(1) The full article can be found online at http://www.sciencedirect.com/science/article/pii/S1096717613000025

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and morestable expression of recombinant proteins.

Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at http://www.prweb.com/releases/metabolic_engineering/therapeutic_proteins/prweb10495971.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. BlowMeCool Inc. Announces a New Affiliate Program for Organizations Promoting Women’s Health & Wellness
2. Schuylkill Medical Associates LLC Announces Job Opening for a House Call Physician
3. VetWebsites (Websites for Veterinarians) Announces Partnership with VetsMyWay to Offer Website Marketing For Veterinarians
4. S.T.A.R. Clinic Announces William Henry as Keynote Speaker at Spring Clinic
5. MinuteHound Announces Monthly Price Plan That Fits Any Business's Budget
6. WeightWise Bariatric Program Announces New Dietician
7. Glidewell Laboratories Announces Customized Implant Component Stocking Inventory
8. The American Cancer Society Announces the Pinecrest Relay For Life Movement Goes Green
9. FileHold Systems Announces: Spanish Language Pack for FileHold Document Management software is now a Standard Feature
10. ACRM
11. American Congress of Rehabilitation Medicine Announces Co-Editors-in-Chief of Archives of Physical Medicine and Rehabilitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... 2016 , ... After a year and a half of planning the Multiple Pathways of ... Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the Mystic ... came together to explore the many pathways individuals use to get into and sustain their ...
(Date:5/27/2016)... Gilsum, New Hampshire (PRWEB) , ... May 27, 2016 , ... ... natural skin care products, announced today that it has been recognized as one of ... men entering parenthood. Badger was named as one of nine small businesses providing progressive ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... to help educate the many who are unaware of the plight of aphasia. ... will run within the “Stroke Awareness” campaign. , The link between stroke and ...
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare industry ... for its inaugural Member Conference at the Paris Hotel in Las Vegas, Nev., ... health of America’s healthcare providers. , The conference was highlighted by the announcement ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharmaceutical company focused on late-stage drug development, ... Dexcel Pharma of pivotal batches required for ... Drug Administration (FDA). This follows Kitov,s announcement ... III trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... According to a new market report ... U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 ... was valued at US$ 5.89 Bn in 2014 and is ... to 2023 to reach US$ 7.99 Bn in 2023. ... needle free drug delivery devices and the market is estimated ...
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
Breaking Medicine Technology: